These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16670649)

  • 21. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
    Gerwe M; Stollhoff K; Mossakowski J; Kuehle HJ; Goertz U; Schaefer C; Bogdanow M; Heger S
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influence of methylphenidate on growth of school age children with attention deficit hyperactivity disorder].
    Zhang HY; Du ML; Zhuang SQ; Liu MN
    Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):723-7. PubMed ID: 16255846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of long-term methylphenidate use on growth and blood pressure: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS).
    McCarthy S; Neubert A; Man KKC; Banaschewski T; Buitelaar J; Carucci S; Coghill D; Danckaerts M; Falissard B; Garas P; Häge A; Hollis C; Inglis S; Kovshoff H; Liddle E; Mechler K; Nagy P; Rosenthal E; Schlack R; Sonuga-Barke E; Zuddas A; Wong ICK
    BMC Psychiatry; 2018 Oct; 18(1):327. PubMed ID: 30305167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of osmotic-release methylphenidate on height and weight in children with attention-deficit hyperactivity disorder (ADHD) following up to four years of treatment.
    Durá-Travé T; Yoldi-Petri ME; Gallinas-Victoriano F; Zardoya-Santos P
    J Child Neurol; 2012 May; 27(5):604-9. PubMed ID: 22190507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD.
    Zhang H; Du M; Zhuang S
    Neuropediatrics; 2010 Aug; 41(2):55-9. PubMed ID: 20799150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of stimulants on height and weight: a review of the literature.
    Faraone SV; Biederman J; Morley CP; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2008 Sep; 47(9):994-1009. PubMed ID: 18580502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands.
    Faber A; van Agthoven M; Kalverdijk LJ; Tobi H; de Jong-van den Berg LT; Annemans L; Postma MJ
    CNS Drugs; 2008; 22(2):157-70. PubMed ID: 18193926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma Methylphenidate Levels in Youths With Attention Deficit Hyperactivity Disorder Treated With OROS Formulation.
    Yorbik O; Mutlu C; Ozilhan S; Eryilmaz G; Isiten N; Alparslan S; Saglam E
    Ther Drug Monit; 2015 Jun; 37(3):347-52. PubMed ID: 25384118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
    Becker SP; Froehlich TE; Epstein JN
    J Dev Behav Pediatr; 2016 Jun; 37(5):395-404. PubMed ID: 27011002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
    Faraone SV; Spencer TJ; Kollins SH; Glatt SJ
    J Am Acad Child Adolesc Psychiatry; 2010 Jan; 49(1):24-32. PubMed ID: 20215923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.
    Silva R; Muniz R; Pestreich LK; Brams M; Childress A; Lopez FA
    J Child Adolesc Psychopharmacol; 2005 Aug; 15(4):637-54. PubMed ID: 16190795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.